Tess Burleson's most recent trade in Salarius Pharmaceuticals Inc was a trade of 20,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 20, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Salarius Pharmaceuticals Inc | Burleson Tess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Salarius Pharmaceuticals Inc | Tess Burleson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,440 | 2,722 (0%) | 0% | 0 | Common Stock | |
| Salarius Pharmaceuticals Inc | Tess Burleson | Director | Purchase of securities on an exchange or from another person at price $ 0.18 per share. | 07 Jun 2022 | 27,700 | 32,050 (0%) | 0% | 0.2 | 4,986 | Common Stock |
| Salarius Pharmaceuticals Inc | Tess Burleson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Salarius Pharmaceuticals Inc | Tess Burleson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) |